We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

33 hedge funds and large institutions have $386M invested in Entrada Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

28% more capital invested

Capital invested by funds: $302M → $386M (+$84.5M)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

0.83% less ownership

Funds ownership: 78.99% → 78.15% (-0.83%)

13% less funds holding

Funds holding: 38 → 33 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
33
Holders Change
-5
Holders Change %
-13.16%
% of All Funds
0.57%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
4
Increased
14
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.79M
2
SG
StepStone Group
California
+$1.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.37M
4
Invesco
Invesco
Georgia
+$1.21M
5
BlackRock
BlackRock
New York
+$1.05M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.71M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.6M
3
CA
CHI Advisors
New York
-$1.99M
4
SCM
Suvretta Capital Management
New York
-$1.29M
5
Millennium Management
Millennium Management
New York
-$932K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$76.7M – – –
MAM
2
MPM Asset Management
Massachusetts
$69.8M – – –
5VM
3
5AM Venture Management
California
$69.5M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$46.8M +$6.79M +534,552 +22%
RG
5
Redmile Group
California
$30.8M – – –
Wellington Management Group
6
Wellington Management Group
Massachusetts
$15.9M -$6.71M -528,637 -34%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.7M +$1.37M +107,783 +14%
SG
8
StepStone Group
California
$12M +$1.6M +126,318 +20%
TCM
9
TCG Crossover Management
California
$10.1M -$273K -21,505 -3%
7IH
10
72 Investment Holdings
Connecticut
$8.02M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$7.94M -$5.6M -441,001 -47%
Goldman Sachs
12
Goldman Sachs
New York
$7.09M +$54.7K +4,307 +1%
LCM
13
Laurion Capital Management
New York
$3.14M +$889K +70,000 +54%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.63M +$830K +65,347 +64%
BlackRock
15
BlackRock
New York
$2.33M +$1.05M +82,594 +127%
NFGH
16
Nan Fung Group Holdings
Hong Kong
$2.23M -$406K -31,989 -18%
MCM
17
Moore Capital Management
New York
$1.66M – – –
Invesco
18
Invesco
Georgia
$1.5M +$1.21M +95,209 New
Charles Schwab
19
Charles Schwab
California
$1.39M +$572K +45,077 +105%
TD Asset Management
20
TD Asset Management
Ontario, Canada
$925K +$23.1K +1,821 +3%
Manulife (Manufacturers Life Insurance)
21
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$640K – – –
State Street
22
State Street
Massachusetts
$525K +$39.4K +3,100 +10%
Northern Trust
23
Northern Trust
Illinois
$473K +$174K +13,669 +84%
FAM
24
Fred Alger Management
New York
$283K +$228K +17,955 New
Morgan Stanley
25
Morgan Stanley
New York
$166K -$135K -10,655 -50%
1
2

TRDA Hedge Fund Activity: Q3 2022 in Review

33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2022, worth a combined $386M — up 28% from $302M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TRDA and 4 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 14 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $6.79M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.

  • 33 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2022, down from 38 in Q2 2022.
  • Funds reported $386M of Entrada Therapeutics stock for Q3 2022, up 28% quarter-over-quarter.
  • 4 funds opened new Entrada Therapeutics positions in Q3 2022 and 9 closed out, a net change of -5 holders.
  • The largest Entrada Therapeutics buyer in Q3 2022 was T. Rowe Price Associates, an estimated $6.79M added.
  • The largest Entrada Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q3 2022.